CAPR

Capricor Therapeutics, Inc. [CAPR] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CAPR Stock Summary

Top CAPR Correlated Resources

CAPR


Top 10 Correlated ETFs

CAPR


Top 10 Correlated Stocks

CAPR


In the News

10:56 29 Mar 2024 CAPR

How Much Upside is Left in Capricor (CAPR)? Wall Street Analysts Think 229.15%

The mean of analysts' price targets for Capricor (CAPR) points to a 229.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

08:30 29 Mar 2024 CAPR

Capricor Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced that the Company is scheduled to present at two upcoming investor conferences.

10:56 29 Mar 2024 CAPR

Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 261.3% in Capricor (CAPR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

08:30 29 Mar 2024 CAPR

Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, will release its financial results for the fourth quarter and full year ended December 31, 2023, after the market close on Thursday, February 29, 2024. Management will then host a webcast and conference call at 4:30 p.m.

08:30 29 Mar 2024 CAPR

Capricor Therapeutics, Inc. (CAPR) Q3 2023 Earnings Call Transcript

Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q3 2023 Results Conference Call November 14, 2023 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marbán - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Aydin Huseynov - Ladenburg Operator Good afternoon, ladies and gentlemen and welcome to the Capricor's Third Quarter 2023 Financial Results and Corporate Update Call.

09:15 29 Mar 2024 CAPR

Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the third quarter ended September 30, 2023, after the market close on Tuesday, November 14, 2023. Management will then host a webcast and conference call at 4:30 p.m.

11:22 29 Mar 2024 CAPR

After Plunging -52.01% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR)

Capricor (CAPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

11:18 29 Mar 2024 CAPR

After Plunging -50.99% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR)

The heavy selling pressure might have exhausted for Capricor (CAPR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

06:42 29 Mar 2024 CAPR

Capricor Therapeutics, Inc. (CAPR) Q2 2023 Earnings Call Transcript

Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q2 2023 Earnings Call Transcript August 7, 2023 4:20 PM ET Company Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Operator Good afternoon, ladies and gentlemen and welcome to the Capricor Therapeutics Second Quarter 2023 Financial Results and Corporate Update Call.

04:01 29 Mar 2024 CAPR

Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the second quarter ended June 30, 2023, after the market close on Monday, August 7, 2023. Management will then host a webcast and conference call at 4:30 p.m.

CAPR Financial details

Company Rating
Neutral
Market Cap
200.33M
Income
394.15M
Revenue
25.18M
Book val./share
0.74
Cash/share
1.29
Dividend
-
Dividend %
-
Employees
101
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
0.35
Forward P/E
67.8
PEG
-0
P/S
11.51
P/B
-75.82
P/C
5.26
P/FCF
-6.9
Quick Ratio
0.88
Current Ratio
0.9
Debt / Equity
0.18
LT Debt / Equity
0.15
-
-
EPS (TTM)
15.63
EPS next Y
0.1
EPS next Q
-0.11
EPS this Y
-29.66%
EPS next Y
-99.38%
EPS next 5Y
-79.62%
EPS last 5Y
-16.05%
Revenue last 5Y
90.44%
Revenue Q/Q
95.42%
EPS Q/Q
-90.04%
-
-
-
-
SMA20
75%
SMA50
40%
SMA100
133.33%
Inst Own
20.39%
Inst Trans
2.02%
ROA
1042%
ROE
8177%
ROC
-7.3%
Gross Margin
45%
Oper. Margin
-220%
Profit Margin
2756%
Payout
-
Shs Outstand
31.4M
Shs Float
28.64M
-
-
-
-
Target Price
-
52W Range
2.68-8.22
52W High
-15.25%
52W Low
+239%
RSI
70
Rel Volume
0.54
Avg Volume
265.3K
Volume
142.86K
Perf Week
-1.02%
Perf Month
79.84%
Perf Quarter
133.79%
Perf Half Y
22.16%
-
-
-
-
Beta
3.955
-
-
Volatility
0.2%, 1.15%
Prev Close
0.15%
Price
6.78
Change
7.79%

CAPR Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.270.020.010.10.94
Net income per share
-1.99-0.87-0.84-1.18-0.83
Operating cash flow per share
-1.84-0.65-0.730.2-0.96
Free cash flow per share
-1.84-0.68-0.780.06-1.03
Cash per share
2.662.11.511.691.47
Book value per share
1.841.821.360.480.84
Tangible book value per share
1.841.821.360.480.84
Share holders equity per share
1.841.821.360.480.84
Interest debt per share
0.910.020.120.040.15
Market cap
4.75M53.23M67.65M94.77M130.95M
Enterprise value
4.23M20.88M35.64M87.73M121.86M
P/E ratio
-0.64-3.95-3.49-3.27-5.88
Price to sales ratio
4.72171.58276.2437.185.2
POCF ratio
-0.7-5.29-4.0219.28-5.12
PFCF ratio
-0.7-5.02-3.7660.87-4.74
P/B Ratio
0.691.892.168.045.79
PTB ratio
0.691.892.168.045.79
EV to sales
4.267.31145.5234.424.84
Enterprise value over EBITDA
-0.54-1.52-1.67-2.91-5.3
EV to operating cash flow
-0.62-2.08-2.1217.84-4.76
EV to free cash flow
-0.62-1.97-1.9856.35-4.41
Earnings yield
-1.55-0.25-0.29-0.31-0.17
Free cash flow yield
-1.44-0.2-0.270.02-0.21
Debt to equity
0.490.010.090.220.18
Debt to assets
0.30.010.070.050.07
Net debt to EBITDA
0.072.361.50.230.39
Current ratio
11.0111.338.821.821.63
Interest coverage
00017.490
Income quality
0.890.740.84-0.171.15
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
3.5817.8731.084.090.49
Research and developement to revenue
5.1227.2655.428.561.42
Intangibles to total assets
00000
Capex to operating cash flow
00.050.07-0.680.08
Capex to revenue
0-1.77-4.88-1.32-0.08
Capex to depreciation
0-3.81-4.87-6.3-1.92
Stock based compensation to revenue
0.76.2912.111.750.29
Graham number
9.085.965.073.573.98
ROIC
-0.73-0.47-0.55-1.76-0.85
Return on tangible assets
-0.66-0.39-0.47-0.58-0.38
Graham Net
1.441.691.090.140.42
Working capital
8.99M30.71M32.3M19.3M19.59M
Tangible asset value
6.83M28.2M31.37M11.79M22.6M
Net current asset value
5.61M27.26M26.47M4.58M14.72M
Invested capital
0.490.010.090.220.18
Average receivables
146.42K71.98K223.88K469.67K5.46M
Average payables
1.08M1.81M3.22M4.28M5.54M
Average inventory
-186.76K-357.68K-28K10.5
Days sales outstanding
31.9565.88583.8778.41150.36
Days payables outstanding
63.75117.595.52K2.54K2.13K
Days of inventory on hand
-46.81-2.42000
Receivables turnover
11.425.540.634.652.43
Payables turnover
5.733.10.070.140.17
Inventory turnover
-7.8-151.02245.7K694.87K0
ROE
-1.08-0.48-0.62-2.46-0.99
Capex per share
0-0.04-0.05-0.14-0.08

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.040.120.150.240.39
Net income per share
-0.3116.19-0.29-0.25-0.02
Operating cash flow per share
-0.270.17-0.37-0.34-0.38
Free cash flow per share
-0.320.15-0.38-0.37-0.4
Cash per share
1.651.791.49K1.11.29
Book value per share
0.470.250.11-0.070.74
Tangible book value per share
0.470.250.11-0.070.74
Share holders equity per share
0.470.250.11-0.070.74
Interest debt per share
0.0616.5587.850.090.13
Market cap
97.13M106.54M121.1M88.3M149.95M
Enterprise value
90.09M98.33M-7.49B81.73M140.86M
P/E ratio
-3.10.07-4.11-3.45-49.19
Price to sales ratio
101.4635.6730.9114.2712.4
POCF ratio
-14.0725.31-12.86-10.04-12.93
PFCF ratio
-11.9628.36-12.55-9.37-12.17
P/B Ratio
8.2417.1744.34-49.396.63
PTB ratio
8.2417.1744.34-49.396.63
EV to sales
94.132.92-1.91K13.2111.65
Enterprise value over EBITDA
-10.71-11.43921.57-11.91-186.47
EV to operating cash flow
-13.0523.36795.35-9.29-12.15
EV to free cash flow
-11.0926.17776.11-8.67-11.43
Earnings yield
-0.083.84-0.06-0.07-0.01
Free cash flow yield
-0.080.04-0.08-0.11-0.08
Debt to equity
0.220.39814.89-1.350.18
Debt to assets
0.050.0448.370.060.07
Net debt to EBITDA
0.840.95936.470.9612.02
Current ratio
1.821.251.110.91.63
Interest coverage
8.16-0.02000
Income quality
0.89-0.541.281.3815.21
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
2.921.180.730.490.25
Research and developement to revenue
6.512.572.251.620.81
Intangibles to total assets
00000
Capex to operating cash flow
0.18-0.110.020.070.06
Capex to revenue
-1.28-0.15-0.06-0.1-0.06
Capex to depreciation
-6.38-1.97-0.92-2.29-2.37
Stock based compensation to revenue
1.20.730.410.280.15
Graham number
1.819.460.840.620.64
ROIC
-0.4839.170-2.16-0.04
Return on tangible assets
-0.167.59-0.16-0.17-0.01
Graham Net
0.14-0.082.25K-0.390.36
Working capital
19.3M9.46M3.77B-3.4M19.59M
Tangible asset value
11.79M6.21M2.73M-1.79M22.6M
Net current asset value
4.58M-1.06M38.88B-9.41M14.72M
Invested capital
0.220.39814.89-1.350.18
Average receivables
547.58K547.58K274.06M274.06M5.46M
Average payables
4.39M5.13M5.28M-3.39B-3.39B
Average inventory
0.5118.88B18.88B0
Days sales outstanding
51.4816.512.58K7.9777.22
Days payables outstanding
2.35K63.741.86K-2.21M1.83K
Days of inventory on hand
0013.69M00
Receivables turnover
1.755.450.0111.31.17
Payables turnover
0.041.410.0500.05
Inventory turnover
185.09K7.66M000
ROE
-0.6665.85-2.73.57-0.03
Capex per share
-0.05-0.02-0.01-0.02-0.02

CAPR Frequently Asked Questions

What is Capricor Therapeutics, Inc. stock symbol ?

Capricor Therapeutics, Inc. is a US stock , located in San diego of Ca and trading under the symbol CAPR

What is Capricor Therapeutics, Inc. stock quote today ?

Capricor Therapeutics, Inc. stock price is $6.78 today.

Is Capricor Therapeutics, Inc. stock public?

Yes, Capricor Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap